3,152 results match your criteria Neutrophilic Eccrine Hidradenitis


Effectiveness of a stop smoking service in reducing cigarette smoking in patients referred from an NHS dermatology centre.

Br J Dermatol 2020 Jul 4. Epub 2020 Jul 4.

Department of Dermatology, University Hospital of Wales, Cardiff, UK.

Cigarette smoking is the leading avoidable cause of mortality in the UK. Individuals who start smoking in early adult life lose 10 years of life expectancy. Smoking is a risk factor for psoriasis [odds ratio (OR) of 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19378DOI Listing

Laser hair reduction for hidradenitis suppurativa warrants insurance coverage.

Dermatol Online J 2020 Apr 15;26(4). Epub 2020 Apr 15.

Department of Medicine, Mount Sinai Icahn School of Medicine Elmhurst Hospital, Elmhurst, NY.

Hidradenitis suppurativa is a chronic, painful disease that significantly reduces quality of life. Laser hair reduction is one modality that can be used in combination with other treatments to ameliorate the condition. We argue that insurance should provide coverage for this necessary service. Read More

View Article

Download full-text PDF

Source

PAPA spectrum disorders.

G Ital Dermatol Venereol 2020 Jul 2. Epub 2020 Jul 2.

Department of Medical-Surgical Pathophysiology and Transplantation, University of Milan, Milan, Italy -

Pyogenic arthritis, pyoderma gangrenosum (PG) and acne (PAPA) syndrome is an autosomal dominant autoinflammatory syndrome due to mutations in proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1) gene and presenting with cutaneous and articular manifestations. Other autoinflammatory syndromes caused by mutations in PSTPIP1 gene or characterized by clinical findings overlapping with those found in PAPA syndrome have been recently included in the group of PAPA spectrum disorders. These disorders are PASH (PG, acne and hidradenitis suppurativa [HS]), PAPASH (PASH associated with pyogenic sterile arthritis), PsAPASH (PASH combined with psoriatic arthritis [PsA], PASS (PG, acne, ankylosing spondylitis, with or without HS), PAC (PG, acne and ulcerative colitis [UC]) and PAMI syndrome (PSTPIP1-associated myeloid-related-proteinemia inflammatory syndrome). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.20.06629-8DOI Listing

Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa.

J Eur Acad Dermatol Venereol 2020 Jul 2. Epub 2020 Jul 2.

Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary.

Background: Numerous generic, skin- and disease-specific health-related quality of life (HRQoL) measures are available for patients with hidradenitis suppurativa (HS). Yet, robust psychometric evidence is lacking in many aspects of these outcome measures.

Objectives: We sought to determine convergent and known-groups validity of multiple generic and skin-specific HRQoL measures and to identify predictors of impaired HRQoL in patients with HS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16642DOI Listing

A Systematic Review andCritical Appraisal of Metagenomic and Culture Studies in Hidradenitis Suppurativa.

Exp Dermatol 2020 Jul 2. Epub 2020 Jul 2.

Laboratory of Investigative Dermatology, Rockefeller University, New York, United States.

Background: Hidradenitis Suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin disease with still largely unknown pathogenesis. While infectious organisms have been identified in lesions of the disease since the 1980s, questions remain over the role that bacteria and microbiome play. Recent studies using 16S ribosomal RNA genesequencing and larger culture-based studies have begun to paint a clearer picture of the microbial world of HS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.14141DOI Listing

Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System.

Dermatology 2020 Jul 1:1-10. Epub 2020 Jul 1.

Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany,

Background: Hidradenitis suppurativa (HS) is a neglected chronic inflammatory disease with long delay in diagnosis. Besides pain, purulent discharge, and destruction of skin architecture, HS patients experience metabolic, musculoskeletal, and psychological disorders.

Objectives: To determine the delay in HS diagnosis and its consequences for patients and the healthcare system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508787DOI Listing

A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.

Dermatol Online J 2020 Mar 15;26(3). Epub 2020 Mar 15.

Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX.

With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated. Tofacitinib, an oral JAK 1/3 inhibitor approved for the treatment of rheumatoid arthritis, has previously been shown to induce significant re-pigmentation in vitiligo. However, as with other novel targeted therapies, cutaneous adverse effects have been observed. Read More

View Article

Download full-text PDF

Source

Doppler Ultrasound-Based Non-Invasive Biomarkers in Hidradenitis Suppurativa: Evaluation of Analytical and Clinical Validity.

Br J Dermatol 2020 Jun 29. Epub 2020 Jun 29.

Laboratory of Investigative Dermatology, The Rockefeller University, Rockefeller, NY, USA.

Background: There is a need for valid and reliable biomarkers in hidradenitis suppurativa (HS) for diagnosis and disease activity monitoring. Imaging-based biomarkers have the potential to fulfill this unmet need but no evaluation of analytical or clinical validity has yet been undertaken.

Objectives: To evaluate the analytical and clinical validity of sonographic epidermal thickness, Doppler ultrasound and dermal tunnel diameter in patients with Hidradenitis Suppurativa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19343DOI Listing

Validation of Patient Global Item for Quality of Life Impact on Hidradenitis Suppurativa.

Br J Dermatol 2020 Jun 29. Epub 2020 Jun 29.

Department of Dermatology, Zealand University Hospital, Health Sciences Faculty, University of Copenhagen, Roskilde, Denmark.

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that is not well understood. The HS core outcome set calls for a patient global assessment (PtGA), for which measures are limited.

Objectives: Our aim is to assess the validity, reliability, and responsiveness of a candidate single-item PtGA for HS-specific health-related quality of life (HRQOL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19344DOI Listing

Global Hidradenitis Suppurativa COVID-19 Registry: A Registry to Inform Data-Driven Management Practices.

Br J Dermatol 2020 Jun 29. Epub 2020 Jun 29.

Patientforeningen HS, Copenhagen, Denmark.

The management of hidradenitis suppurativa (HS), a chronic inflammatory skin disease, deserves special consideration in the context of the Coronavirus 2019 (COVID-19) pandemic. A new Global Hidradenitis Suppurativa COVID-19 Registry has been developed to capture data on risks, clinical course, and outcomes of COVID-19 in HS patients. Caused by the virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), COVID-19 is an easily transmissible disease which, in its most severe form, is characterized by respiratory failure and multiple organ dysfunction triggered by a cytokine storm response that predominates in older adults and those with significant comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19345DOI Listing

Grand Rounds: Multimodal surgical management of severe scrotal lymphedema and buried penis.

Urology 2020 Jun 25. Epub 2020 Jun 25.

Harvard Medical School, Boston, Mass; Division of Plastic Surgery, Brigham & Women's Hospital, Boston, Mass. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2020.06.016DOI Listing

Intralesional Ultrasound-Guided Combined Treatment With Triamcinolone Plus Lincomycin In Hidradenitis Suppurativa: A Pilot Study.

Dermatol Ther 2020 Jun 26. Epub 2020 Jun 26.

Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy.

Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory, disease of the hair follicle. Intralesional corticosteroid treatment in HS patients has been reported, and while several data described this route of administration as an efficient delivery system, its efficacy is still debated.

Objective: The aim of this study was to explore the clinical efficacy and the effect on quality of life (QoL) of an innovative intralesional treatment in HS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13901DOI Listing

Infliximab-induced neutrophilic eccrine hidradenitis in a patient with hidradenitis suppurativa.

Dermatol Ther 2020 Jun 26:e13900. Epub 2020 Jun 26.

Dermatology, Emek Medical Center, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13900DOI Listing

The Importance of Methodological Rigor in Proof-of-Concept Clinical Trials: A Lesson from Hidradenitis Suppurativa.

J Invest Dermatol 2020 Jun 17. Epub 2020 Jun 17.

Laboratory of Investigative Dermatology, Rockefeller University, New York, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2020.03.977DOI Listing

Interactive, Proof of Concept Clinical Trial Design in Hidradenitis Suppurativa (HS).

Authors:
Alice Gottlieb

J Invest Dermatol 2020 Jun 20. Epub 2020 Jun 20.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2020.06.006DOI Listing

Lymph node involvement in hidradenitis suppurativa: Ultrasound and color Doppler study of 85 patients.

Skin Res Technol 2020 Jun 25. Epub 2020 Jun 25.

UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/srt.12896DOI Listing

Hidradenitis Suppurativa - Prevalence Analyses of German Statutory Health Insurance Data.

J Eur Acad Dermatol Venereol 2020 Jun 24. Epub 2020 Jun 24.

Psoriasis Research and Treatment Centre, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Hidradenitis suppurativa (HS) is a chronic, inflammatory disease affecting the intertriginous skin of axillary, inguinal, and perianal sites. In these areas, patients develop painful and disabling skin lesions such as inflamed nodules, abscesses, and fistula with foul-smelling secretions. We aimed to investigate the documented prevalence and health care of HS patients in Germany. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16783DOI Listing

Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance.

Br J Dermatol 2020 Jun 24. Epub 2020 Jun 24.

Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.

Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects the hair follicle in the apocrine gland-bearing regions. Although HS is not primarily caused by bacterial infection, antibiotics represent the first line treatment in the management of HS primarily for their anti-inflammatory properties, with additional contributions via antimicrobial and immunomodulatory effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19337DOI Listing

Remote management of hidradenitis suppurativa in a pandemic era of COVID-19.

Int J Dermatol 2020 Jun 23. Epub 2020 Jun 23.

Division of Dermatology, Women's College Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.15022DOI Listing

Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism.

Actas Dermosifiliogr 2020 Jun 19. Epub 2020 Jun 19.

Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, España. Electronic address:

Spironolactone is an economical potassium-sparing diuretic with an anti-androgenic effect and a good safety profile. Our experience suggests that this diuretic is underexploited in dermatology even though there is evidence supporting its use in several skin conditions. When prescribed for acne in female patients (level 1-2 evidence; strength of recommendation, B), for example, it can reduce the need for antibiotics and possibly isotretinoin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2020.03.001DOI Listing

Ex Vivo Models and Interpretation of Mechanistic Studies in Hidradenitis Suppurativa.

J Invest Dermatol 2020 Jul;140(7):1323-1326

Division of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada. Electronic address:

Current ex vivo and animal models of hidradenitis suppurativa (HS) display issues with fidelity and validity to human disease. Vossen et al.'s Transwell culture system holds potential to reliably assess mechanistic pathways in HS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2020.02.014DOI Listing

Cellulitis-like Sweet Syndrome caused by adalimumab therapy for severe hidradenitis suppurativa.

Australas J Dermatol 2020 Jun 22. Epub 2020 Jun 22.

Departments of, Department of, Dermatology, Hospital Universitari Arnau de Vilanova de Lleida, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.13349DOI Listing

Hidradenitis Suppurativa Recurrence in a Caesarean Scar.

Case Rep Obstet Gynecol 2020 3;2020:6283720. Epub 2020 Jun 3.

Veracity Clinical Research, Suite 18 Level 1 250 Ipswich Rd., Woolloongabba QLD 4102, Australia.

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, relapsing inflammatory skin condition characterised by the presence of painful nodules, abscesses, and sinus tracts or scarring. Affecting up to 4% of the population, it is not uncommon and is seen predominantly in females at a ratio of 3 : 1. HS carries a substantial burden for those who suffer from it, from the significant psychosocial impact, to the cost of the multitude of topical and systemic treatments which often do not successfully control its symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/6283720DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291312PMC

Atypical Hidradenitis Suppurativa on the Leg in a Psoriatic Patient.

Indian J Dermatol 2020 May-Jun;65(3):231-232

Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_20_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292468PMC

Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa.

J Am Acad Dermatol 2020 Jun 18. Epub 2020 Jun 18.

Department of Dermatology, Hôpital Saint Louis, AP-HP, Paris; Université de Paris, Paris; laboratory of Genetics of Skin Diseases, UMR Inserm U1163, Institut Imagine, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.06.042DOI Listing

Association of retinol binding protein4 (RBP4) and ghrelin plasma levels with insulin resistance and disease severity in non-diabetic patients with hidradenitis suppurativa.

Exp Dermatol 2020 Jun 21. Epub 2020 Jun 21.

Division of Internal Medicine, Hospital Universitario Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain.

Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with insulin resistance (IR). Retinol binding protein 4 (RBP4) and ghrelin are two bioactive proteins that have been involved in glucose metabolism and IR, but also in the regulation of immune and inflammatory processes. The aim of this study was to determine the serum levels of RBP4 and ghrelin in patients with HS, and to assess the possible relationship between these levels and IR, disease severity and HS risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.14132DOI Listing

Immunomodulatory Drugs Alone and Adjuvant to Surgery for Hidradenitis Suppurativa/ Acne Inversa - A Narrative Review.

Dermatol Ther 2020 Jun 19:e13877. Epub 2020 Jun 19.

Faculty of Health, University Witten/Herdecke, Witten, Germany.

Hidradenitis suppurativa/ acne inversa (HS/AI) is one of the most debilitating dermatoses with a strong negative impact on every dimension of quality of life. Treatment is dependent on the severity of clinical manifestations and comorbidities. While anti-inflammatory and antimicrobial approaches are recommended for mild and moderate stages, immunomodulatory drugs have gained increasing interest in all stages of HS/AI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13877DOI Listing

Management of patients with Hidradenitis Suppurativa during the COVID-19 pandemic.

Dermatol Ther 2020 Jun 19:e13875. Epub 2020 Jun 19.

Department of Dermatology at Hospital Universitario Virgen de las Nieves, Granada, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13875DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323050PMC

Efficacy of topical Ichthammol 10% for Hidradenitis Suppurativa: case series and systematic review of its use in dermatology.

Authors:
S Fisher M Ziv

Dermatol Ther 2020 Jun 18:e13868. Epub 2020 Jun 18.

Dermatology and Venereology Clinic, Emek Medical Center, Afula, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13868DOI Listing

Effect of Hidradenitis Suppurativa Disease Duration on Psychiatric Comorbidity.

Acta Derm Venereol 2020 Jun 18. Epub 2020 Jun 18.

Department of Dermatology, University of Oulu, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3577DOI Listing

Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab.

Actas Dermosifiliogr 2020 Jun 15. Epub 2020 Jun 15.

Unidad de Gestión Clínica de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Puerta del Mar, Cádiz, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2019.07.007DOI Listing

Pleiotropic Role of Notch Signaling in Human Skin Diseases.

Int J Mol Sci 2020 Jun 13;21(12). Epub 2020 Jun 13.

Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.

Notch signaling orchestrates the regulation of cell proliferation, differentiation, migration and apoptosis of epidermal cells by strictly interacting with other cellular pathways. Any disruption of Notch signaling, either due to direct mutations or to an aberrant regulation of genes involved in the signaling route, might lead to both hyper- or hypo-activation of Notch signaling molecules and of target genes, ultimately inducing the onset of skin diseases. The mechanisms through which Notch contributes to the pathogenesis of skin diseases are multiple and still not fully understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21124214DOI Listing

Severe hidradenitis suppurativa successfully treated with secukinumab.

Dermatol Ther 2020 Jun 16:e13845. Epub 2020 Jun 16.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13845DOI Listing

Teledermatology and chronic skin diseases: real life experience in a Southern Italian Dermatologic Centre.

Dermatol Ther 2020 Jun 15:e13839. Epub 2020 Jun 15.

Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13839DOI Listing

Tackling key immunological and immuno-dermatological pathways and their link to treatment options.

Authors:
Daniel Boda

Exp Ther Med 2020 Jul 4;20(1):9-11. Epub 2020 May 4.

Research Laboratory, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2020.8712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282104PMC

Further evidence for the immediate knowledge improvement through EADV Schools on hidradenitis suppurativa/acne inversa.

J Eur Acad Dermatol Venereol 2020 Jun 13. Epub 2020 Jun 13.

European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16744DOI Listing

Topical antibiotics in the dermatological clinical practice: indications, efficacy and adverse effects.

Dermatol Ther 2020 Jun 12:e13824. Epub 2020 Jun 12.

Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Bari, Bari, Italy.

Topical antibiotic therapy is a central component of patient management for several skin conditions, including acne, hidradenitis suppurativa, rosacea, impetigo or other superinfected dermatitis, prevention of wound infections. Moreover, particular situations, such as skin diseases of bacterial origin in pregnancy and infants often warrant topical therapy. However, the occurrence of local delayed hypersensitivity reactions and the rising rate of antibiotic resistance are becoming great challenges faced by many dermatologists today. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13824DOI Listing

Sexual impairment in patients with hidradenitis suppurativa: a systematic review.

J Eur Acad Dermatol Venereol 2020 Jun 12. Epub 2020 Jun 12.

Instituto de Investigación Biosanitaria Granada, Granada, Spain.

Background: Hidradenitis suppurativa (HS) can cause considerable impact on several aspects of quality of life. Sexuality is a central aspect of quality of life. In recent years there has been an increase in the number of articles on HS and sexuality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16726DOI Listing

Risk of connective tissue disease, morphea and systemic vasculitis in patients with hidradenitis suppurativa.

J Eur Acad Dermatol Venereol 2020 Jun 12. Epub 2020 Jun 12.

Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, United States.

Background: Hidradenitis suppurativa (HS) has been associated with auto-inflammatory conditions, yet the risk of developing connective tissue disease (CTD), morphea, and systemic vasculitis has not been well-characterized.

Objectives: We sought to evaluate the risk of developing CTD, morphea and systemic vasculitis in patients with HS.

Methods: Using claims data we identified patients with HS and used 2:1 risk-set sampling to identify patients without HS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16728DOI Listing

Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.

Aliment Pharmacol Ther 2020 Jul 11;52(2):303-310. Epub 2020 Jun 11.

Department of Dermatology, Cochin Hospital, AP-HP, Paris, France.

Background: Crohn's disease (CD) and hidradenitis suppurativa (HS), a chronic inflammatory skin disease, induce similar inflammatory lesions of the groin and gluteal area. Both diseases are characterised by an inadequate immune response to commensal bacteria in genetically predisposed subjects and can be associated.

Aim: To assess whether HS was associated with clinical and prognostic factors in CD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15863DOI Listing
July 2020
5.727 Impact Factor

Hidradenitis suppurativa through the lens of YouTube: a cross-sectional analysis.

J Am Acad Dermatol 2020 Jun 6. Epub 2020 Jun 6.

Division of Dermatology, Harbor-UCLA Medical Center, Torrance, CA; Department of Medicine, The Lundquist Institute, Torrance, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.05.148DOI Listing

Dermatologic conditions in Down syndrome: A single-center retrospective chart review.

Pediatr Dermatol 2020 Jun 10. Epub 2020 Jun 10.

Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, USA.

Background: Current literature addressing dermatologic conditions associated with Down syndrome is limited, with emphasis on rare skin conditions and lack of consensus on the incidence of more common disorders.

Objective: We sought to evaluate dermatologic conditions in patients with Down syndrome diagnosed and managed by dermatologists.

Methods: This was a retrospective analysis of 101 pediatric and adult patients with Down syndrome seen by the University of Massachusetts Dermatology Department between 2008 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.14214DOI Listing

Altered keratinization and vitamin D metabolism may be key pathogenetic pathways in syndromic hidradenitis suppurativa: a novel whole exome sequencing approach.

J Dermatol Sci 2020 May 22. Epub 2020 May 22.

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Physiopathology and Transplantation, Università degli Studi di Milano Via Pace 9, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. Electronic address:

Background: Diagnosis of pyoderma gangrenosum, acne and hidradenitis suppurativa (PASH) and pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH) patients, in spite of recently identified genetic variations, is just clinical, since most patients do not share the same mutations, and the mutations themselves are not informative of the biological pathways commonly disrupted in these patients.

Objective: To reveal genetic changes more closely related to PASH and PAPASH etiopathogenesis, identifying novel common pathways involved in these diseases.

Methods: Cohort study on PASH (n = 4) and PAPASH (n = 1) patients conducted using whole exome sequencing (WES) approach and a novel bioinformatic pipeline aimed at discovering potentially candidate genes selected from density mutations and involved in pathways relevant to the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2020.05.004DOI Listing

MABp1 targeting interleukin-1alpha in hidradenitis suppurativa non-eligible for adalimumab treatment: Results of the open-label extension period.

Clin Exp Dermatol 2020 Jun 9. Epub 2020 Jun 9.

4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.

The emerging situation of patients with moderate-to-severe hidradenitis suppurativa (HS) non-eligible for or not responding to adalimumab generates the unmet need for new therapies. In a previous small-scale randomized clinical trial, MABp1 (also known as bermekimab) showed 60% treatment efficacy compared to 10% of placebo in such patient population. Eight of patients originally randomized to placebo treatment were allowed to participate in an open-label extension (OLE) treatment with MABp1 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.14333DOI Listing

Proposed Definitions of Typical Lesions in Hidradenitis Suppurativa.

Dermatology 2020 Jun 9:1-8. Epub 2020 Jun 9.

Private practice, Paris, France.

Background: Although not rare, hidradenitis suppurativa (HS) is often under-recognized by physicians. The diagnosis of HS is clinical via the recognition of lesions typical of the disease, but universally accepted definitions of these latter are currently lacking, which means that certain severity scores employed for HS classification/management are used differently by different physicians. Our aim was to develop a set of descriptive definitions and associated images of HS lesions, in order to enable doctors to better recognize and evaluate the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507348DOI Listing

LAight® Therapy Improves Hidradenitis Suppurativa in Patients Declining Surgical Intervention: Two Case Reports.

Acta Derm Venereol 2020 Jun 18;100(13):adv00193. Epub 2020 Jun 18.

Dermatology Outpatient Office Dr. Daniela Kasche, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3558DOI Listing

Male granulomatous mastitis with hidradenitis suppurativa, a rarely encountered disorder.

Breast J 2020 Jun 9. Epub 2020 Jun 9.

Department of Breast Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.13899DOI Listing

What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?

Br J Dermatol 2020 Jun 8. Epub 2020 Jun 8.

Department of Dermatology & Wound Healing, Division of Infection and Immunity, Cardiff University, University Hospital of Wales, 3 rd Floor Glamorgan House, Heath Park, Cardiff, CF14 4XN, U.K.

A previous survey demonstrated the management of hidradenitis suppurativa (HS) in the UK in 2014 and subsequently, in 2018, the first UK guidelines for the management of HS were published. We recently repeated the survey to evaluate whether there has been a change in the management of HS influenced by the guidelines and new HS treatment evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19302DOI Listing